CYP3A4 mutation causes vitamin D–dependent rickets type 3

Jeffrey D. Roizen, …, Hakon Hakonarson, Michael A. Levine


Genetic forms of vitamin D–dependent rickets (VDDRs) are due to mutations impairing activation of vitamin D or decreasing vitamin D receptor responsiveness. Here we describe two unrelated patients with early-onset rickets, reduced serum levels of the vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and deficient responsiveness to parent and activated forms of vitamin D. Neither patient had a mutation in any genes known to cause VDDR; however, using whole exome sequencing analysis, we identified a recurrent de novo missense mutation, c.902T>C (p.I301T), in CYP3A4 in both subjects that alters the conformation of substrate recognition site 4 (SRS-4). In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency.

Find the latest version:

http://jci.me/98680/pdf
CYP3A4 mutation causes vitamin D–dependent rickets type 3

Jeffrey D. Roizen,1 Dong Li,2 Lauren O’Lear,1 Muhammad K. Javaid,3 Nicholas J. Shaw,4 Peter R. Ebeling,5 Hanh H. Nguyen,5 Christine P. Rodda,6 Kenneth E. Thummel,7 Tom D. Thacher,8 Hakon Hakonarson,2 and Michael A. Levine1

1Division of Endocrinology and Diabetes and 2Center for Applied Genomics, The Children’s Hospital of Philadelphia (CHOP), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. 4Department of Endocrinology and Diabetes, Birmingham Children’s Hospital and Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom. 5Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia. 6Australian Institute for Musculoskeletal Science, Sunshine Hospital, and Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia. 7Department of Pharmaceutics, University of Washington, Seattle, Washington, USA. 8Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Genetic forms of vitamin D–dependent rickets (VDDRs) are due to mutations impairing activation of vitamin D or decreasing vitamin D receptor responsiveness. Here we describe two unrelated patients with early-onset rickets, reduced serum levels of the vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and deficient responsiveness to parent and activated forms of vitamin D. Neither patient had a mutation in any genes known to cause VDDR; however, using whole exome sequencing analysis, we identified a recurrent de novo missense mutation, c.902T>C (p.I307T), in CYP3A4 in both subjects that alters the conformation of substrate recognition site 4 (SRS-4). In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency.

Introduction

Vitamin D deficiency rickets is a childhood disorder associated with impaired growth and skeletal mineralization. In most cases, vitamin D deficiency is due to inadequate exposure to sunlight and/or insufficient dietary vitamin D (1). Vitamin D is biologically inactive and undergoes 2 enzymatic conversions to become fully active 1,25-dihydroxyvitamin D. The existence of rickets in areas with abundant sunlight has led to the identification of genetic forms of vitamin D–dependent rickets (VDDRs). Type 1 VDDRs are caused by defects in vitamin D activation, owing to mutations in the genes encoding either the renal 1-α hydroxylase (CYP27B1: VDDR-1A) (2) or the hepatic 25-hydroxylase (CYP2R1: VDDR-1B) (3, 4). Type 2 VDDRs are caused by defects in vitamin D receptor signaling due to mutations in the gene encoding the vitamin D receptor (VDR: VDDR-2A); or heterogeneous nuclear ribonucleoprotein C (HNRNPC: VDDR-2B) (5, 6), a VDR coactivator. Vitamin D homeostasis is also regulated by renal 24-hydroxylase (CYP24A1), an enzyme responsible for 24-oxidation of 1,25-dihydroxyvitamin D3 to inactive calcitriol (7) and degradation of 25-hydroxyvitamin D3 to inactive 24,25-dihydroxyvitamin D3 (8). Here we describe a third kind of VDDR (VDDR-3), in which a gain-of-function mutation in CYP3A4, which encodes a P450 enzyme that metabolizes many xenobiotics and drugs, leads to vitamin D deficiency through accelerated vitamin D metabolite inactivation.

Results and Discussion

Clinical and biochemical studies. We studied 2 unrelated females from non-consanguineous families. Both subjects were born full-term with normal birth weight and length. Proband 1.1 presented to medical attention prior to age 2 years with a history of bowed legs and unsteady gait noted at 20 months. Her pediatrician diagnosed rickets on the basis of bilateral genu varum, poor growth, and reduced serum calcium and phosphorus with elevated serum alkaline phosphatase and parathyroid hormone (Table 1). She was of European ancestry and lived in a sunny climate in Australia. At age 2.5 years she was referred for endocrine evaluation, at which time her height was 81.3 cm (6th percentile) and weight was 11.5 kg (35th percentile). Proband 2.1 was of Middle Eastern descent and did not walk until 4.5 years of age. She was treated for rickets in Jordan, Spain, and the Netherlands prior to evaluation in the United Kingdom at age 16 years, when she had a height of 154.3 cm (9th percentile). Wrist radiographs in both subjects showed features consistent with active rickets (Figure 1A). Both subjects had detectable serum vitamin D3, but low serum levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (Table 1), which increased only after administration of very large doses of vitamin D or calcitriol and declined rapidly thereafter. After oral administration of 50,000 IU of vitamin D3, proband 1.1 showed a normal increase in serum cholecalciferol, indicating normal absorption of vita-
of substrate recognition site 4 (SRS-4), one of 6 SRSs determining CYP3A4 substrate selectivity and product profile (10). SIFT (http://sift.jcvi.org/) and MutPred (http://mutpred.mutdb.org/) predict this change would damage function, but MutPred additionally predicts a possible novel catalytic function. To examine the possibility of a common genetic origin of the mutation, we determined CYP3A4 gene haplotypes in both families. No common haplotype was shared by the 2 mutation carriers, excluding the possibility of a common founder.

**Functional assessment of the CYP3A4 p.I301T mutant.** Because previous work had shown that p.I301 is a determinant of activity for CYP3A4 SRS-4 substrates (11), we hypothesized that threonine replacement of isoleucine 301 might increase oxidation of the vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (12, 13). We tested this hypothesis by analyzing serum 4,25-dihydroxyvitamin D, the principal product of CYP3A4 metabolism of 25-hydroxyvitamin D (14, 15). In both subjects, the ratio of 4β,25-dihydroxyvitamin D to 25-dihydroxyvitamin D was markedly elevated to the range of values exhibited by patients taking rifampin (16), an inducer of CYP3A4 (Table 1). We next used a mammalian cell 2-hybrid expression system in which intracellular 1,25-dihydroxyvitamin stimulates transcription of a luciferase reporter gene (4) to assess the ability of the mutant recombinant CYP3A4 protein to inactivate 1,25-dihydroxyvitamin D. Cells expressing mutant compared with WT recombinant CYP3A4 protein had decreased luciferase activity, indicating that p.I301T possessed greater ability to inactivate 1,25-dihydroxyvitamin D (Figure 2A) than WT (P < 0.01 for overall curves; post hoc multiple comparison–adjusted analyses confirmed significance at 0.03 ng/ml [mean difference: 0.13; 95% CI, 0.08–0.22], 0.1 ng/ml [mean difference: 0.72; 95% CI, 0.25–1.20], 0.3 ng/ml [mean difference: 2.03; 95% CI, 1.55–2.51], and 1 ng/ml [mean difference: 3.6; 95% CI, 3.1–4.1]; P < 0.01 for each). Moreover, p.I301T CYP3A4 was more active than CYP24A1, the principal inactivator of 1,25-dihydroxyvitamin D, at 0.3 ng/ml (mean difference: 0.42; 95% CI, 0.06–0.77; P < 0.05). We also compared apparent kinetics data between enzymes, as measurements were performed using reporter activity in whole cells. The apparent catalytic efficiency

### Table 1. Biochemical analyses

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2.2–2.8</td>
<td>12–18</td>
<td>16–6.9</td>
<td>130–450</td>
<td>75–160</td>
<td>151–730</td>
<td>208–682</td>
<td>22–60</td>
<td>206–588</td>
<td>0.74–3.59</td>
<td>25–125</td>
<td>20,000–50,000</td>
</tr>
<tr>
<td>Proband 1.1</td>
<td>27 mo</td>
<td>1.67</td>
<td>1.14</td>
<td>58.3</td>
<td>2,826</td>
<td>&lt;16</td>
<td>47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proband 1.1 vitamin D response test</td>
<td>20 yr</td>
<td>6.0</td>
<td>18.8</td>
<td>679.2</td>
<td>207</td>
<td>20.7</td>
<td>174</td>
<td>6.05</td>
<td>62.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proband 2.1</td>
<td>16 yr</td>
<td>1.87</td>
<td>0.97</td>
<td>70.8</td>
<td>1,269</td>
<td>16.5</td>
<td>&lt;20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

[Image 42x404 to 548x726]

[Image 42x751]

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

The Journal of Clinical Investigation

**CONCISE COMMUNICATION**

1915

**jci.org** Volume 128 Number 5 May 2018

Figure 1. CYP3A4 mutation causes VDDR. (A) Wrist radiographs of the 2 probands are consistent with those of untreated rickets despite high-dose supplementation. Wrist radiographs from these patients show the typical features of rickets: younger growing patients have bowing (green triangle), metaphyseal splaying (yellow triangle), and cupping (red triangle), as in proband 1.1 (P 1.1); older patients have metaphyseal lucency (blue triangle) and osteopenia (purple triangle), as in proband 2.1; features change as the role of calcification changes with age (supporting growth vs. maintaining bone integrity). (B) Family pedigrees are consistent with p.I301T mutations arising de novo. Family pedigrees of the 2 probands with Sanger sequencing results of the mutation region in CYP3A4 from all available family members. (C) Alignment of CYP3A4 protein sequence surrounding p.I301T mutation reveals high conservation of this residue across species. Isoleucine 301 is highly conserved in CYP3A4 across evolution and within the human 3A protein family.

Figure 1. CYP3A4 mutation causes VDDR. (A) Wrist radiographs of the 2 probands are consistent with those of untreated rickets despite high-dose supplementation. Wrist radiographs from these patients show the typical features of rickets: younger growing patients have bowing (green triangle), metaphyseal splaying (yellow triangle), and cupping (red triangle), as in proband 1.1 (P 1.1); older patients have metaphyseal lucency (blue triangle) and osteopenia (purple triangle), as in proband 2.1; features change as the role of calcification changes with age (supporting growth vs. maintaining bone integrity). (B) Family pedigrees are consistent with p.I301T mutations arising de novo. Family pedigrees of the 2 probands with Sanger sequencing results of the mutation region in CYP3A4 from all available family members. (C) Alignment of CYP3A4 protein sequence surrounding p.I301T mutation reveals high conservation of this residue across species. Isoleucine 301 is highly conserved in CYP3A4 across evolution and within the human 3A protein family.

[Image 42x404 to 548x726]

[Image 42x751]
metabolites 25-hydroxvitamin D and 1,25-dihydroxyvitamin D (15).

Although the impact of CYP3A4 on vitamin D homeostasis is limited under physiological conditions, under special circumstances CYP3A4 can have significant effects on vitamin D metabolism. For example, induction of CYP3A4 by anticonvulsants is associated with vitamin D deficiency (15). In addition, targeted induction of CYP3A4 by rifampin provides an alternative clearance mechanism for vitamin D.

**Figure 2.** CYP3A4 (p.I301T) mutant has increased vitamin D degradative activity but decreased activity for other substrates. (A) CYP3A4 (p.I301T) has increased vitamin D degradative activity. CYP3A4 p.I301T had increased inactivation of calcitriol relative to WT (**P < 0.01 by 2-way ANOVA for curve), and post hoc multiple comparison–adjusted analyses confirmed significant differences at 0.03, 0.1, and 0.3 ng/ml (**P < 0.01) and relative to CYP24A1 at 0.3 ng/ml (**P < 0.05) (n = 3 for each). (B and C) There is no difference in the relative abundance of the WT and p.I301T CYP3A4 (n = 3 for each treatment). (B) Immunoblot of cell lysates for CYP3A4 and GAPDH. (C) Quantification of the relative abundance of CYP3A4 and GAPDH. No significant differences were observed between the abundance of the WT and the p.I301T mutant. (D) CYP3A4 (p.I301T) does not have increased catalytic activity for non–vitamin D substrates. The p.I301T mutant had significantly decreased activity for luciferin IPA relative to the WT enzyme (30.0 ± 1.6 vs. 50.1 ± 1.6, n = 4 for each, ***P < 0.001). **P < 0.05. Data are presented as mean ± SEM.

mutation unlikely and is most consistent with recurrent independent mutation events. CYP3A4 (Enzyme Commission [EC] 1.14.13.97) is the most abundant P450 in the liver and is also highly expressed in the intestine. CYP3A4 serves an important metabolic role in biotransforming a wide variety of compounds, including many drugs, steroids, xenobiotics, and carcinogens. Most relevant to this work, CYP3A4 can oxidize and inactivate the vitamin D metabolites 25-hydroxvitamin D and 1,25-dihydroxyvitamin D (15). Although the impact of CYP3A4 on vitamin D homeostasis is limited under physiological conditions, under special circumstances CYP3A4 can have significant effects on vitamin D metabolism. For example, induction of CYP3A4 by anticonvulsants is associated with vitamin D deficiency (15). In addition, targeted induction of CYP3A4 by rifampin provides an alternative clearance mechanism for vitamin D.

**Figure 3.** Pathogenesis of VDDR. VDDR-1s are caused by mutations in genes encoding proteins that activate vitamin D: CYP2R1 and CYP27B1. VDDR-2s are caused by mutations in genes encoding signal transducing proteins: VDR and HNRNPC. Type 3 is due to gain-of-function mutations in a gene encoding a vitamin D–degrading enzyme: CYP3A4.
that can normalize elevated vitamin D metabolites in patients who lack the native pathway for vitamin D oxidation due to loss-of-function mutations in CYP24A1 (16). Finally, common polymorphisms in CYP3A4 are associated with decreased bone density (20).

Several lines of evidence support our hypothesis that the p.I301T CYP3A4 mutation is the basis for a selective defect in vitamin D metabolism. First, the 2 affected subjects had elevated 4β,25-dihydroxyvitamin D/25-hydroxyvitamin D ratios but normal 4β-hydroxycholesterol. Second, molecular modeling and in vitro studies previously identified isoleucine 301 as an important determinant of substrate binding; and that replacing isoleucine 301 with another nonconservative residue, phenylalanine, results in 4-fold increases in CYP3A4 activity for some substrates (10, 14). Third, our in vitro studies showed that p.I301T CYP3A4 significantly increased inactivation of 1,25-dihydroxyvitamin D$_3$ but had no effect on clearance of substrate luciferin IPA. Although we did not measure other steroid hormones in the 2 patients, there was no clinical evidence of additional endocrine defects. Therefore, the genetic gain of function in CYP3A4 recapitulated the selective inactivation of vitamin D metabolites well described in patients taking drugs that induce CYP3A4 (21).

These observations lead us to propose that a gain-of-function mutation of CYP3A4 causes a distinct form of VDDR. In contrast to the previously described autosomal recessive forms of VDDR that result from defects in either synthesis of vitamin D metabolites or responsiveness to 1,25-dihydroxyvitamin D, this dominant form of VDDR is due to accelerated inactivation of vitamin D metabolites (schematic of VDDRs in Figure 3). Although nutritional vitamin D deficiency is the most common cause of childhood rickets, these 2 cases, representing the identification of a previously undescribed VDDR, emphasize the importance of considering accelerated vitamin D inactivation as a risk factor for vitamin D deficiency. There is renewed awareness of the importance of daily vitamin D prophylaxis for the prevention of vitamin D deficiency and rickets in infants and children, and our findings highlight the importance of genetic and induced variation in CYP3A4 activity as a modifier of the amount of vitamin D necessary to maintain vitamin D homeostasis.

Methods

For further information, see Supplemental Methods.

Biochemical and molecular analyses. We measured serum and urine electrolytes, serum creatinine, and parathyroid hormone using routine methods. Measurements of vitamin D$_3$, vitamin D$_2$, 25-hydroxyvitamin D$_3$, 25-hydroxyvitamin D$_2$, 24,25-dihydroxyvitamin D, and 4β-hydroxycholesterol were performed by isotope dilution liquid chromatography–tandem mass spectrometry. We measured serum 1,25-dihydroxyvitamin D$_3$ and 4β,25-dihydroxyvitamin D$_3$ using an ultrahigh resolution chromatographic separation procedure (15) that enables their complete separation.

We performed whole-exome sequencing of DNA from proband 1.1, proband 2.1, and their available relatives (Figure 1), as described previously (22). Analysis of candidate genes and CYP3A4 confirmation genotyping were performed by Sanger sequencing. Analysis of 1,25-dihydroxyvitamin D degradative activity of WT and mutant CYP3A4 recombinant proteins was performed using a mammalian 2-hybrid expression system in which activity of firefly luciferase is proportional to the concentration of intracellular 1,25-dihydroxyvitamin D (see Supplemental Methods and ref. 4). Activity against other substrates was assayed by measuring CYP3A4 conversion of luciferin IPA to the luminescent luciferin.

Cell lines. HEK293T cells were obtained from ATCC (catalog CRL-3216).

In vitro assessment of expression and activity of CYP3A4. Mutations were introduced by PCR site-directed mutagenesis into a full-length human CYP3A4 cDNA (provided by P.F. Hollenberg, University of Michigan; ref. 23).

Statistics. All assays were performed in biological quadruplicate. All statistical analyses were performed using GraphPad Prism 7. Sample means were compared using a t test or ANOVA with Tukey’s 2-tailed post hoc test as appropriate, with a P value of 0.05 defined as statistically significant. All data are presented as mean ± SEM.

Study approval. All studies were approved by the institutional review board of the Children’s Hospital of Philadelphia. Patients or parents provided written informed consent/assent prior to inclusion in the study.

Author contributions

JDR prepared the manuscript and contributed to the study design and data analyses. DL and HH performed and interpreted the whole exome sequence analyses. LO performed assays and collected data. MKJ, NJS, PRE, HHN, CPR, KET, and TDT contributed to study design, collection of clinical and biochemical data, and characterization of the subjects’ phenotypes. MAL contributed to overall study design, data analysis, interpretation, and preparation of the manuscript. All authors reviewed and approved the final manuscript.

Acknowledgments

We thank Brian Phillips for help examining vitamin D metabolites and Harsh Kanwar for assistance in performing assays. This study was supported in part by grants from the NIH (R01 DK079790 and R01 DK112955 to MAL; KO8 HD087964 to JDR), the Children’s Hospital of Philadelphia Research Institute (to MAL), and the Institutional Development Fund to the Center for Applied Genomics from the Children’s Hospital of Philadelphia (to HH). MKJ was supported by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC).

Address correspondence to: Michael A. Levine, Children’s Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, Pennsylvania 19103, USA. Phone: 215.590.3907; Email: levinem@chop.edu.

4. Thacher TD, Fischer PR, Singh RJ, Roizen J, Levine MA. CYP2R1 mutations impair generation of 25-hydroxyvitamin D and cause an atyp-
The Journal of Clinical Investigation

CONCISE COMMUNICATION


